Some studies have shown that IFN-β compounds can reduce MS attacks, brain atrophy, and the number and volume of brain lesions.3,11 Other studies have suggested the better effects of low dose IFN-β-A and high dose (REBIF) in reducing plaques in MRI compared with placebo.13 This evidence concerns the gene IFNB1 and myeloid sarcoma.